Mesalamine Extended-Release Capsules
Failed Dissolution Specifications: Out of specification for dissolution.
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.
Cause type: Microbial contamination
Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.
Mesalamine Delayed-Release Tablets, USP 1.2 g per tablet, Rx Only, 120 Tablets per bottle, Once Daily, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Survey No. 259/15, Dadra-396 191 (U.T. of D & NH), INDIA, NDC 63304-175-13.
Compare with the code on your package — it is the most precise check available.
Drug: Mesalamine
From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.
| Product | Strength | Form & route | Labeler | Type |
|---|---|---|---|---|
| Mesalamine NDC 63304-0175 |
1.2 g/1 | Tablet, Delayed Release Oral |
Sun Pharmaceutical Industries, Inc. | Rx |
Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.
Failed Dissolution Specifications: Out of specification for dissolution.
Failed Dissolution Specifications
Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during stability testing.
Failed Dissolution Specifications: Low out of specification dissolution result observed during stability testing.
Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules
Failed Stability Specifications
CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing
Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.
Failed Impurities/Degradation Specifications
Free recall alerts
Tell us what you take. When FDA posts a recall announcement or classifies a recall for one of your medications, we email you in plain English, with what to check. No account needed.